Lymphoma Clinical Trials in Atlanta

Showing 101-120 of 543 trials

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+12 more

Mayo Clinic565 participantsStarted Mar 2013

Scottsdale, Arizona, United States • Atlanta, Georgia, United States • Iowa City, Iowa, United States +2 more locations

RECRUITINGPhase 1/2< 1 mile

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Haematological MalignancyAcute Myeloid LeukemiaNon Hodgkin Lymphoma+3 more

CellCentric Ltd.250 participantsStarted Aug 2019

Atlanta, Georgia, United States • Indianapolis, Indiana, United States • Bethesda, Maryland, United States +36 more locations

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Lymphoma Trials in Other Cities

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Other Conditions in Atlanta